Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

Several other equities analysts also recently weighed in on the company. Piper Jaffray Companies reiterated an “overweight” rating and set a $30.00 target price on shares of Adamas Pharmaceuticals in a research report on Wednesday, October 4th. Noble Financial restated a “buy” rating and set a $33.00 price target on shares of Adamas Pharmaceuticals in a research note on Friday, September 29th. Mizuho restated a “buy” rating and set a $48.00 price target (up from $26.00) on shares of Adamas Pharmaceuticals in a research note on Tuesday, September 19th. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Adamas Pharmaceuticals in a research note on Sunday, September 17th. Finally, ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. Adamas Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $39.50.

Adamas Pharmaceuticals (NASDAQ:ADMS) traded down 2.03% on Tuesday, hitting $21.69. The stock had a trading volume of 853,934 shares. The stock’s market cap is $488.33 million. The stock’s 50 day moving average is $20.71 and its 200 day moving average is $17.68. Adamas Pharmaceuticals has a one year low of $12.10 and a one year high of $24.18.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter in the previous year, the business earned ($0.78) EPS. The company’s revenue for the quarter was down 90.9% compared to the same quarter last year. Analysts anticipate that Adamas Pharmaceuticals will post ($3.77) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Adamas Pharmaceuticals, Inc. (ADMS) Upgraded to “Hold” at Zacks Investment Research” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/10/adamas-pharmaceuticals-inc-adms-upgraded-to-hold-at-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently made changes to their positions in ADMS. Tower Research Capital LLC TRC bought a new stake in shares of Adamas Pharmaceuticals in the 2nd quarter worth approximately $109,000. American International Group Inc. lifted its holdings in shares of Adamas Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after purchasing an additional 682 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in shares of Adamas Pharmaceuticals in the 2nd quarter worth approximately $184,000. Wells Fargo & Company MN lifted its holdings in shares of Adamas Pharmaceuticals by 28.4% in the 1st quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after purchasing an additional 3,358 shares during the last quarter. Finally, Alps Advisors Inc. lifted its holdings in shares of Adamas Pharmaceuticals by 6.7% in the 2nd quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock worth $353,000 after purchasing an additional 1,272 shares during the last quarter. 69.16% of the stock is currently owned by institutional investors and hedge funds.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.